Nasdaq · Healthcare
Fortress Biotech, Inc. (FBIO)
As-reported financials and recent SEC filings for Fortress Biotech, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$63.3M
Net income
$6.8M
Net margin
10.8%
Diluted EPS
$-0.07
ROE
11.0%
P/E (TTM)
—
Market cap
—
Debt / equity
0.9×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $63.3M | $57.7M | $84.5M | $75.7M | $68.8M |
| Gross profit | $42.3M | $36.8M | $61.6M | $45.0M | $36.7M |
| Operating income | $-70.2M | $-110.4M | $-142.3M | $-203.6M | $-188.5M |
| Net income | $6.8M | $-46.0M | $-60.6M | $-86.6M | $-64.7M |
| Diluted EPS | $-0.07 | $-2.69 | $-2.82 | $-5.32 | $-3.69 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-24
View on EDGAR →8-K2026-06-23
View on EDGAR →SCHEDULE 13G/A2026-05-15
View on EDGAR →10-Q2026-05-14
View on EDGAR →8-K2026-05-14
View on EDGAR →DEFA14A2026-04-28
View on EDGAR →DEF 14A2026-04-28
View on EDGAR →42026-04-01
View on EDGAR →Largest Healthcare peers
Go deeper on FBIO
Search Fortress Biotech, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.